Special Issue "Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines—Correlates of Immunogenicity Parameters with Protection?"

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "SARS-CoV-2 and COVID-19".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editor

Dr. Zoltan Vajo
E-Mail Website
Guest Editor
Department of Family Medicine, Semmelweis University Medical School, 1125 Budapest, Hungary
Interests: influenza; vaccines; serology; clinical trials

Special Issue Information

Dear Colleagues,

During the assessment and licensing of novel vaccines, and in the post-licensure follow up, it is critical to have reliable immunogenicity-testing methods that relate well to protection. The need for reliable immunogenicity criteria became apparent in preparation for the potential pandemic threat posed by influenza A H5N1 in 2006, when great intra- and interlaboratory variations were seen for hemagglutinin inhibition and microneutralization tests, and the need for a centralized standard was acknowledged by the WHO and NIBSC.

In the case of SARS-CoV-2, this remains a critical issue, as many different antibody tests have been developed urgently, but with unknown correlation to real-world protection. Therefore, collaboration among different laboratories and health authorities is essential to establish standards and to reduce interlaboratory variations, and to establish immunogenicity correlates that can be used for licensing as well as patient care. In this Special Issue, we seek papers discussing the development of reliable immunogenicity tests that correlate with the real-world protection of SARS-CoV-2 and other novel vaccines.

Sub-topics: antibody levels; cellular immunity; correlates of protection; rapid vs laboratory antibody kits; the role of ELISA

Dr. Zoltan Vajo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • SARS-CoV-2
  • serology
  • cellular immune response
  • protection
  • vaccines

Published Papers

This special issue is now open for submission.
Back to TopTop